Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15279945 | 0.89 | AGTR2 (0.42) | CA1CA2CA4CA9AGTR2 | |
| SCHEMBL2017921 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL4709100 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL4709252 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL27764711 | 0.83 | NR1H2 (0.44) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL27786520 | 0.83 | NR1H2 (0.45) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL21274222 | 0.81 | NR1H2 (0.46) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL8114204 | 0.81 | NR1H2 (0.50) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL17376945 | 0.80 | NR1H2 (0.48) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL26914975 | 0.80 | NR1H2 (0.46) | NR1H2NR1H3CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | NR1H2 302/4885NR1H3 382/4885CA1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.